COVID-19 Tedavisinde Favipiravir Kullanımı
Yıl: 2021 Cilt: 26 Sayı: 1 Sayfa Aralığı: 1 - 11 Metin Dili: Türkçe DOI: 10.5578/flora.20219901 İndeks Tarihi: 20-05-2021
COVID-19 Tedavisinde Favipiravir Kullanımı
Öz: Aralık 2019 tarihinde tanımlanan yeni koronavirüs hastalığı (COVID-19) için etken olan SARS-CoV-2’ye karşı etkinliği kısmen gösterilmiş tedavi seçenekleri olmakla birlikte sağ kalım üzerine etkisi kanıtlanmış bir ilaç henüz geliştirilememiştir. Farklı endikasyonlar için kulla-nılmakta veya geliştirilmekte olan birçok kimyasal, in vitro çalışmalarda gözlenen etkilerine dayanılarak, tedavi amaçlı kullanıma alın-mıştır. Bu ilaçlardan biri olan favipiravir ilk olarak pandeminin başlangıç merkezi olan Wuhan’da kullanılmıştır. İnfeksiyonun dünyaya yayılmaya başlamasından itibaren İtalya, Japonya, Rusya, Ukrayna, Özbekistan, Moldova ve Kazakistan, Bangladeş, Mısır, Hindistan gibi ülkelerin yanı sıra ülkemizde de kullanılmaktadır. Favipiravirin etkinliğini değerlendirmek için yapılmış ve yayımlanmış az sayıda çalışma vardır ancak çok sayıda çalışma devam etmektedir. Bu derlemede literatürde favipiravirin COVID-19 tedavisinde etkinliğini bildi-ren çalışma ve vaka raporlarının gözden geçirilmesi ve değerlendirilmesi amaçlanmıştır. Kaynak taramasıyla 223 sonuca ulaşılmıştır, bu sonuçlardan 210 yazıya tam erişim sağlanabilmiştir ve toplam 34 yazı analize dahil edilmiştir. Derleme kapsamında favipiravirin farma-kolojisi başlığı altında farmakokinetik, farmakodinamik özelliklere ek olarak istenmeyen etkiler ve ilaç etkileşimlerinden bahsedilmiştir. Favipiravir, COVID-19 hastalarının tedavisi için seçeneklerden biridir ancak çok daha fazla hastanın dahil edildiği ve daha uzun takip sürelerini içeren randomize, kontrollü çalışmaların planlanması ve devam eden çalışmaların sonuçlarının değerlendirmesi gerekmektedir.
Anahtar Kelime: Favipiravir Use in COVID-19 Treatment
Öz: There are treatment options with partially shown efficacy against SARS-CoV-2. A drug with proven effect on survival has not yet been developed for the new coronavirus disease (COVID-19) defined in December 2019. Many chemicals that are being used or developed for different indications have been used for COVID-19 treatment, based on their effects observed in in vitro studies. Favipiravir, one of these drugs, was first used in Wuhan, the starting center of the pandemic. Since the spread of the infection to the world, it has been used in our country as well as countries such as Italy, Japan, Russia, Ukraine, Uzbekistan, Moldova and Kazakhstan, Bangladesh, Egypt, India. There are few studies conducted and published to evaluate the effectiveness of favipiravir, but many studies are ongoing. In this review, it was aimed to review and evaluate the studies and case reports reporting the efficacy of favipiravir in the treatment of COVID-19. With the literature search, 223 results were reached, 210 articles were fully accessed, and a total of 34 articles were included in the analysis. In the scope of the review, under the title of pharmacology of favipiravir, adverse effects and drug interactions in addition to pharmaco-kinetic and pharmacodynamic properties are mentioned. Favipiravir is one of the options for the treatment of COVID-19 patients, but randomized, controlled trials involving much more patients and longer follow-up periods need to be planned and the results of ongoing trials evaluated.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- 1. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013;100(2):446-54.
- 2. Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 2014;105:17-21.
- 3. Sissoko D, Laouenan C, Folkesson E, M’Lebing AB, Beavogui AH, Baize S, et al. Experimental treatment with favipiravir for Ebola Virus Disease (the JIKI Trial): A historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med 2016;13(3):e1001967.
- 4. Bouazza N, Treluyer J-M, Foissac F, Mentré F, Taburet A-M, Guedj J, et al. Favipiravir for children with Ebola. Lancet 2015;385(9968):603-4.
- 5. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research 2020;30(3):269-71.
- 6. Du Y-X, Chen X-P. Favipiravir: Pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin Pharmacol Ther 2020;108(2):242-7.
- 7. Toyama Chemicals. Summary of Product Characteristics of Avigan. Accessed date: 17.12.2020 Available from: https:// www.cdc.gov.tw/File/Get/ht8jUiB_MI-aKnlwstwzvw,
- 8. Madelain V, Nguyen TH, Olivo A, de Lamballerie X, Guedj J, Taburet AM, et al. Ebola Virus infection: Review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clin Pharmacokinet 2016;55(8):907-23.
- 9. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 2017;93(7):449-63.
- 10. Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, et al. A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19. Antimicrob Agents Chemother 2020;64(12):e01897-20.
- 11. Eloy P, Solas C, Touret F, Mentré F, Malvy D, de Lamballerie X, et al. Dose rationale for favipiravir use in patients infected with SARS-CoV-2. Clin Pharmacol Ther 2020;108(2):188.
- 12. Irie K, Nakagawa A, Fujita H, Tamura R, Eto M, Ikesue H, et al. Pharmacokinetics of favipiravir in critically ill patients with COVID-19. Clin Transl Sci 2020;13(5):880-5.
- 13. Hirai D, Yamashita D, Seta K. Favipiravir for COVID-19 in a patient on hemodialysis. Am J Kidney Dis 2020:S0272- 6386(20)31006-4.
- 14. Pharmaceuticals and Medical Devices Agency. Report on the Deliberation Results Avigan, Japan. Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau. Available date: 17.12.2020. Available from: www.pmda. go.jp/files/000210319.pdf.
- 15. Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic? J Virus Eradication 2020;6(2):45-51.
- 16. Kumagai Y, Murakawa Y, Hasunuma T, Aso M, Yuji W, Sakurai T, et al. Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults. Int J Clin Pharmacol Ther 2015;53(10):866-74.
- 17. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering (Beijing) 2020;6(10):1192-8.
- 18. Yamamura H, Matsuura H, Nakagawa J, Fukuoka H, Domi H, Chujoh S. Effect of favipiravir and an anti-inflammatory strategy for COVID-19. Crit Care 2020;24(1):413.
- 19. Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN, et al. AVIFAVIR for treatment of patients with moderate COVID-19: Interim results of a phase II/III multicenter randomized clinical trial. Clin Infect Dis 2020 Aug 9:ciaa1176.
- 20. Fu D, Cao R, Zhao L, Li W, Zhong W, Wen J. Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series. Crit Care 2020;24(1):578.
- 21. Çalik Başaran N, Uyaroğlu OA, Telli Dizman G, Özişik L, Şahin TK, Taş Z, et al. Outcome of non-critical COVID-19 patients with early Hospitalization and early antiviral treatment outside the ICU. Turk J Med Sci 2020 Jul 28.
- 22. Doi K, Ikeda M, Hayase N, Moriya K, Morimura N. Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series. Crit Care 2020;24(1):392.
- 23. Kocayiğit H, Özmen Süner K, Tomak Y, Demir G, Yaylacı S, Dheir H, et al. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19. J Clin Pharm Ther 2020 Oct 31.
- 24. Lou Y, Liu L, Yao H, Hu X, Su J, Xu K, et al. Clinical outcomes and plasma concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 patients: An exploratory randomized, controlled trial. Eur J Pharm Sci 2020:105631.
- 25. Cura Yayla BC, Özsürekçi Y, Aykaç K, Derin Oygar P, Laçinel Gürlevik S, İlbay S, et al. Characteristics and management of children with COVID-19 in Turkey. Balkan Med J 2020;37(6):341-7.
- 26. Yaylaci S, Dheir H, Şenocak D, Genc AB, Kocayigit H, Çekiç D, et al. The effects of favipiravir on hematological parameters of cov1d-19 patients. Revista da Associação Médica Brasileira. 2020;66:65-70.
- 27. Koba H, Yoneda T, Kaneda T, Ueda T, Kimura H, Kasahara K. Severe coronavirus disease 2019 (COVID-19) pneumonia patients treated successfully with a combination of lopinavir/ ritonavir plus favipiravir: Case series. Clin Case Rep 2020:10.1002/ccr3.3358
- 28. Dauby N, Van Praet S, Vanhomwegen C, Veliziotis I, Konopnicki D, Roman A. Tolerability of favipiravir therapy in critically ill patients with COVID-19: A report of four cases. J Med Virol 2020 Sep 4.
- 29. Takahashi H, Iwasaki Y, Watanabe T, Ichinose N, Okada Y, Oiwa A, et al. Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition. Int J Infect Dis 2020;100:283-285.
- 30. Hosoba R, Makita S, Shiotsuka M, Kobayashi O, Nakano K, Muroya M, et al. COVID-19 pneumonia in a patient with adult T-cell leukemia-lymphoma. J Clin Exp Hematop 2020;60(4):174-178.
- 31. Murohashi K, Hagiwara E, Kitayama T, Yamaya T, Higa K, Sato Y, et al. Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases. Respir Investig 2020;58(6):430-4.
- 32. Inoue H, Jinno M, Ohta S, Kishino Y, Kawahara T, Mikuni H, et al. Combination treatment of short-course systemic corticosteroid and favipiravir in a successfully treated case of critically ill COVID-19 pneumonia with COPD. Respir Med Case Rep 2020;31:101200.
- 33. Taşkın B, Vural S, Altuğ E, et al. Coronavirus 19 presenting with atypical Sweet’s syndrome. J Eur Acad Dermatol Venereol 2020;34(10):e534-e5.
- 34. Takahashi N, Abe R, Hattori N, Matsumura Y, Oshima T, Taniguchi T, et al. Clinical course of a critically ill patient with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). J Artif Organs 2020:1-4.
- 35. Nakamura H, Miyagi K, Otsuki M, Higure Y, Nishiyama N, Kinjo T, et al. Acute hypertriglyceridaemia caused by tocilizumab in a patient with severe COVID-19. Intern Med 2020;59(22):2945-9.
- 36. Thammathiwat T, Tungsanga S, Tiankanon K, Torvorapanit P, Chumpangern W, Udomkarnjananun S, et al. A case of successful treatment of severe COVID-19 pneumonia with favipiravir and tocilizumab in post-kidney transplant recipient. Transpl Infect Dis 2020:e13388-e.
- 37. Yatomi M, Takazawa T, Yanagisawa K, Kanamoto M, Matsui Y, Tsukagoshi H, et al. Improvement of severe COVID-19 in an elderly man by sequential use of antiviral drugs. Case Rep Infect Dis 2020;2020:8814249.
- 38. Sugiyama Y, Tsuchiya T, Tanaka R, Ouchi A, Motoyama A, Takamoto T, et al. Cerebral venous thrombosis in COVID-19-associated coagulopathy: A case report. J Clin Neurosci 2020;79:30-2.
- 39. Tatar E, Karatas M, Bozaci I, Ari A, Acar T, Simsek C, et al. Intravenous immunoglobulin and favipiravir treatment for a kidney transplant patient with severe Covid-19 pneumonia. Transfus Apher Sci 2020:102904.
- 40. Ono K, Kishimoto M, Shimasaki T, Uchida H, Kurai D, Deshpande GA, et al. Reactive arthritis after COVID-19 infection. RMD Open 2020;6(2):e001350.
- 41. Koshi E, Saito S, Okazaki M, Toyama Y, Ishimoto T, Kosugi T, et al. Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019. CEN Case Rep 2020:1-6.
- 42. Jafari R, Jonaidi-Jafari N, Dehghanpoor F, Saburi A. Convalescent plasma therapy in a pregnant COVID-19 patient with a dramatic clinical and imaging response: A case report. World J Radiol 2020;12(7):137-41.
- 43. Sakamaki I, Morinaga Y, Tani H, Takegoshi Y, Fukui Y, Kawasuji H, et al. Monitoring of viral load by RT-PCR caused decision making to continue ECMO therapy for a patient with COVID-19. J Infect Chemother 2020;26(12):1324-7.
- 44. Kondo Y, Miyazaki S, Yamashita R, Ikeda T. Coinfection with SARS-CoV-2 and influenza A virus. BMJ Case Rep 2020;13(7):e236812.
- 45. Moolasart V, Wongsawat J, Phokhom P, Thienthong V. Favipiravir- based regimen for coronavirus disease 2019 pneumonia for a 47-day-old male newborn. SAGE Open Med Case Rep 2020;8:2050313x20964046.
- 46. Hase R, Kurata R, Ishida K, Kurita T, Muranaka E, Mito H. Acute gouty arthritis during favipiravir treatment for Coronavirus Disease 2019: A case report. Intern Med 2020;59(18):2327-9.
- 47. Takoi H, Togashi Y, Fujimori D, Kaizuka H, Otsuki S, Wada T, et al. Favipiravir-induced fever in coronavirus disease 2019: A report of two cases. Int J Infect Dis 2020;101:188-90.
| APA | Kara E, Inkaya A, Demirkan K, Unal S (2021). COVID-19 Tedavisinde Favipiravir Kullanımı. , 1 - 11. 10.5578/flora.20219901 |
| Chicago | Kara Emre,Inkaya Ahmet Cagkan,Demirkan Kutay,Unal Serhat COVID-19 Tedavisinde Favipiravir Kullanımı. (2021): 1 - 11. 10.5578/flora.20219901 |
| MLA | Kara Emre,Inkaya Ahmet Cagkan,Demirkan Kutay,Unal Serhat COVID-19 Tedavisinde Favipiravir Kullanımı. , 2021, ss.1 - 11. 10.5578/flora.20219901 |
| AMA | Kara E,Inkaya A,Demirkan K,Unal S COVID-19 Tedavisinde Favipiravir Kullanımı. . 2021; 1 - 11. 10.5578/flora.20219901 |
| Vancouver | Kara E,Inkaya A,Demirkan K,Unal S COVID-19 Tedavisinde Favipiravir Kullanımı. . 2021; 1 - 11. 10.5578/flora.20219901 |
| IEEE | Kara E,Inkaya A,Demirkan K,Unal S "COVID-19 Tedavisinde Favipiravir Kullanımı." , ss.1 - 11, 2021. 10.5578/flora.20219901 |
| ISNAD | Kara, Emre vd. "COVID-19 Tedavisinde Favipiravir Kullanımı". (2021), 1-11. https://doi.org/10.5578/flora.20219901 |
| APA | Kara E, Inkaya A, Demirkan K, Unal S (2021). COVID-19 Tedavisinde Favipiravir Kullanımı. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, 26(1), 1 - 11. 10.5578/flora.20219901 |
| Chicago | Kara Emre,Inkaya Ahmet Cagkan,Demirkan Kutay,Unal Serhat COVID-19 Tedavisinde Favipiravir Kullanımı. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi 26, no.1 (2021): 1 - 11. 10.5578/flora.20219901 |
| MLA | Kara Emre,Inkaya Ahmet Cagkan,Demirkan Kutay,Unal Serhat COVID-19 Tedavisinde Favipiravir Kullanımı. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, vol.26, no.1, 2021, ss.1 - 11. 10.5578/flora.20219901 |
| AMA | Kara E,Inkaya A,Demirkan K,Unal S COVID-19 Tedavisinde Favipiravir Kullanımı. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi. 2021; 26(1): 1 - 11. 10.5578/flora.20219901 |
| Vancouver | Kara E,Inkaya A,Demirkan K,Unal S COVID-19 Tedavisinde Favipiravir Kullanımı. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi. 2021; 26(1): 1 - 11. 10.5578/flora.20219901 |
| IEEE | Kara E,Inkaya A,Demirkan K,Unal S "COVID-19 Tedavisinde Favipiravir Kullanımı." Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, 26, ss.1 - 11, 2021. 10.5578/flora.20219901 |
| ISNAD | Kara, Emre vd. "COVID-19 Tedavisinde Favipiravir Kullanımı". Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi 26/1 (2021), 1-11. https://doi.org/10.5578/flora.20219901 |
